Member Info for Arbitrage

it is my assertion that the newly focused BOD of 'FAST' could, do a lot worse than put their evaluative slide-rule over an acquisition of either (or indeed both) ValiRx and Sareum Holdings as, given the current stage of these Companies respective pipeline development of multiple targeted disease cures in areas of significant 'unmet need', both offer significant upside potential and both are, imo, run by BOD's who evidently are completely lacking in fiscal and business acumen.

http://www.investegate.co.uk/salt-lake-potash-ltd--so4-/rns/december-2015-quarterly-report/201601290700083849N/

http://www.investegate.co.uk/oxford-pharmascience--oxp-/rns/entering-partnering-discussions/201601250700108277M/

my sincere apologies, I posted this on the wrong BB it was intended for and will be re-posted on the New World Oil & Gas BB.

http://www.investegate.co.uk/fastnet-equity-plc--fast-/rns/appointment-of-non-executive-director/201512210701056573J/

http://www.investegate.co.uk/fastnet-equity-plc--fast-/rns/demerger-of-oil-and-gas-assets/201512180700075242J/

http://www.lse.co.uk/sharecast-news-article.asp?ArticleCode=23718863&ArticleHeadline=Reckitt_Benckiser_ordered_to_pull_Nurofen_range_in_Australia

Given that you have now had your hand on the tiller for circa 3 months, I for one would be very grateful to receive news via an rns as to how the implementation of your plans in respect of our Cos are progressing. Many thanks in anticipation.

as exemplified by the content of the latest RNS (see below) which, the BOD issued on the 5 November 2015 an extract from which, contained the following comment from our CEO: Marcelo Bravo, Chief Executive Officer, commented: "We are very pleased with the data package on OXPzeroTM Ibuprofen which demonstrates this is a compound with potential to disrupt the market, delivering a range of key benefits that provide clear and compelling differentiation. The body of data shows this is a versatile and flexible technology that can allow major brand owners to create and sustain competitive advantage in the large and growing ibuprofen market through multiple brand extension options. In the coming weeks, we will be completing preparation of commercial discussion materials with the aim of seeking a partner for the OXPzeroTM Ibuprofen platform. We look forward to updating shareholders in due course. We continue making great progress with other key NSAIDs, namely OXPzeroTM Naproxen, OXPzeroTM Diclofenac and OXPzeroTM Aspirin and also evaluating further targets. Additional announcements will be made as appropriate." http://www.investegate.co.uk/oxford-pharmascience--oxp-/rns/successful-completion-of-poc-for-oxpzero-ibuprofen/201511050700066225E/ Further to the above and as a long-term strategic investor in this Cos, along with a several high-profile Institutional Investors, I am personally delighted with the progress which, this Cos has made to date and continues to evidence and exhibit. In conclusion, I hold the BOD of this Cos in very high esteem and I have high expectations in their ability to deliver significant returns to shareholders over the course of the next few weeks/months. Best wishes to all medium and long-term investors in this Cos.

Lake Wells drill results exceeds wildest expectations: http://www.investegate.co.uk/wildhorse-energy--whe-/rns/drilling-confirms-deeper-potential-at-lake-wells/201511230700065416G/

http://www.investegate.co.uk/wildhorse-energy--whe-/rns/significant-maiden-sop-resource-at-lake-wells/201511110700072573F/

http://www.proactiveinvestors.co.uk/companies/news/117118/redx-pharma-shares-nudge-higher-as-it-makes-two-senior-appointments-117118.html

http://www.investegate.co.uk/oxford-pharmascience--oxp-/rns/successful-completion-of-poc-for-oxpzero-ibuprofen/201511050700066225E/

http://www.investegate.co.uk/tower-resources-plc--trp-/rns/operational-update-and-interim-results/201509300700366292A/ In light of the above and imo, Graeme Thomson's position is completely untenable and he should now do the honorable thing and resign.

which, I view as positive, does however, throw-up in my mind just one niggling little doubt (or, given TRP's market cap of circa £12.5m), maybe not so little and it is in respect of the following issues, extracted from today's rns: >Initial Exploration Period (3 Years): Consisting of geological and geophysical studies, 100km2 of 3D seismic acquisition and a commitment well with a minimum financial commitment of US$13 million. >First Renewal Period (2 Years): Consisting of one exploration or appraisal well with a minimum financial commitment of US$15 million. >Second Renewal Period (2 Years): Consisting of one exploration or appraisal well with a minimum financial commitment of US$15 million. How is the above to be funded? Surely, I ask, with a faint hint of sarcasm, given the BOD of this Cos 'track record', could it be via the issuance of equity and yet further dilution of shareholders holdings?!

http://www.express.co.uk/life-style/health/602872/Simple-aspirin-drugs-defeat-cancers-new-treatment Further to the above, and given the BOD of OXP 's stated aim to develop Aspirin as a future disease cure, then a potential joint-venture partnership with Sareum Holdings (SAR) would, given SAR's 'best-in-class' CHK1 compound, has the makings of a 'marriage made in heaven!'

as a 'going concern', surely lies in shareholders supporting and endorsing the BOD, as they move forward with their proposal to transform the Cos via either a 'reverse take-over' or preferably, imo, via two or, possibly three strategic investments into existing biopharma Cos with an existing and identifiable pipeline of oncology drugs/compounds close to or at 'key-inflexion' stage (of which, there are several currently evident e.g. Valirx, Sareum, Rene, Oxp). re Fastnet's Oil & Gas interests: In additon to the above (and were I a member of the Fastnet BOD), I would strongly recommend to my fellow BOD Members that Fastnet (i.e.The Company), look to extract maximum future shareholder value in respect of its Celtic Sea 3D Seismic data (of which, $18 million of shareholders funds has been 'ploughed-in' to its acquisition). In so doing, I would seek to 'leverage' Fastnet's very strong position via the negotiation of a % 'farm-in' to any future single or, multi-well drilling program on behalf of Fastnet's shareholders using the 3D Seismic Data as the 'bargaining chip' to facilitate this with whichever Cos subsequently acquires Fastnet's soon to be relinquished licences and in so doing we, as the shareholders in Fastnet, may yet benefit and enjoy some subsequent return on our investment which, despite all the previous rhetoric and high expectations has, to date, come to nought! In addition, if the BOD elect to follow this suggestion, then the value of said 3D assets can both be maintained and continue to be reflected in Fastnet's accounts/market cap.

http://www.investegate.co.uk/fastnet-oil---38--gas--fast-/rns/director-pdmr-shareholding/201506261445233911R/

Fastnet Oil & Gas (LON:FAST) A corporate update from Fastnet Oil & Gas where the team are knuckling down and cutting costs whilst also looking at appropriate M&A opportunities. The former has been pretty successful with costs down over 40% and still falling, whilst relatively new CEO Carol Law has been looking at a number of deals without yet finding the right one. I would much rather it was this way round that making a wrong call and there must be plenty of opportunities in the offing. With $16.2m of cash the company is well placed and when the right deal comes along they will be able to take advantage of the situation. Intriguingly the Molly Malone and Mizzen options have expired and the company has re-submitted new licence applications on high graded portions in the area which again seems like common sense. I recently met with the company and will do so again before too long but the policy of cutting costs, preserving cash and identifying possible new opportunities looks pretty sound to me.

put simply, the BOD of this Cos are in the immortal words of Terry Thomas, "an absolutely shower" but hey-ho, they're the ones laughing all the way to the bank at shareholders expense! Maybe a corporate re-brand is called for to 'TRP: The Driller of Perpetual Dusters!"